Spinogenix reports top line outcomes from trial of therapy for Fragile X syndrome
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
Zacks Investment Research on MSN22h
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...